135 related articles for article (PubMed ID: 33469550)
1. A Light-Inducible Split-dCas9 System for Inhibiting the Progression of Bladder Cancer Cells by Activating p53 and E-cadherin.
Huang X; Zhou Q; Wang M; Cao C; Ma Q; Ye J; Gui Y
Front Mol Biosci; 2020; 7():627848. PubMed ID: 33469550
[TBL] [Abstract][Full Text] [Related]
2. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells.
Liu Y; Zeng Y; Liu L; Zhuang C; Fu X; Huang W; Cai Z
Nat Commun; 2014 Nov; 5():5393. PubMed ID: 25373919
[TBL] [Abstract][Full Text] [Related]
3. Integration and exchange of split dCas9 domains for transcriptional controls in mammalian cells.
Ma D; Peng S; Xie Z
Nat Commun; 2016 Oct; 7():13056. PubMed ID: 27694915
[TBL] [Abstract][Full Text] [Related]
4. An Efficient Light-Inducible P53 Expression System for Inhibiting Proliferation of Bladder Cancer Cell.
Lin F; Dong L; Wang W; Liu Y; Huang W; Cai Z
Int J Biol Sci; 2016; 12(10):1273-1278. PubMed ID: 27766041
[TBL] [Abstract][Full Text] [Related]
5. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
Shieh GS; Shiau AL; Yo YT; Lin PR; Chang CC; Tzai TS; Wu CL
Cancer Res; 2006 Oct; 66(20):9957-66. PubMed ID: 17047058
[TBL] [Abstract][Full Text] [Related]
6. Synthetic circuits based on split Cas9 to detect cellular events.
Przybyszewska-Podstawka A; Czapiński J; Kałafut J; Rivero-Müller A
Sci Rep; 2023 Sep; 13(1):14988. PubMed ID: 37696879
[TBL] [Abstract][Full Text] [Related]
7. Synthetic miRNA sponges driven by mutant hTERT promoter selectively inhibit the progression of bladder cancer.
Zhuang CL; Fu X; Liu L; Liu YC; Huang WR; Cai ZM
Tumour Biol; 2015 Jul; 36(7):5157-63. PubMed ID: 25775949
[TBL] [Abstract][Full Text] [Related]
8. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.
Qin Y; Tang B; Hu CJ; Xiao YF; Xie R; Yong X; Wu YY; Dong H; Yang SM
Oncotarget; 2016 Jan; 7(1):351-61. PubMed ID: 26540342
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer.
Liu L; Liu Y; Zhang T; Wu H; Lin M; Wang C; Zhan Y; Zhou Q; Qiao B; Sun X; Zhang Q; Guo X; Zhao G; Zhang W; Huang W
J Exp Clin Cancer Res; 2016 Jan; 35():3. PubMed ID: 26743236
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-dCas9-Guided and Telomerase-Responsive Nanosystem for Precise Anti-Cancer Drug Delivery.
Ma Y; Mao G; Wu G; Cui Z; Zhang XE; Huang W
ACS Appl Mater Interfaces; 2021 Feb; 13(7):7890-7896. PubMed ID: 33513005
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells.
Deng WG; Jayachandran G; Wu G; Xu K; Roth JA; Ji L
J Biol Chem; 2007 Sep; 282(36):26460-70. PubMed ID: 17630431
[TBL] [Abstract][Full Text] [Related]
12. Complex transcriptional modulation with orthogonal and inducible dCas9 regulators.
Gao Y; Xiong X; Wong S; Charles EJ; Lim WA; Qi LS
Nat Methods; 2016 Dec; 13(12):1043-1049. PubMed ID: 27776111
[TBL] [Abstract][Full Text] [Related]
13. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
14. Multiple Input Sensing and Signal Integration Using a Split Cas12a System.
Kempton HR; Goudy LE; Love KS; Qi LS
Mol Cell; 2020 Apr; 78(1):184-191.e3. PubMed ID: 32027839
[TBL] [Abstract][Full Text] [Related]
15. Telomerase suppression initiates PML-dependent p53 activation to inhibit bladder cancer cell growth.
Xue Y; Li L; Zhang D; Wu K; Guo P; Zeng J; Wang X; He D
Oncol Rep; 2010 Dec; 24(6):1551-9. PubMed ID: 21042751
[TBL] [Abstract][Full Text] [Related]
16. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
17. An Inducible CRISPR-dCas9-Based Transcriptional Repression System for Cancer Therapy.
Gu P; Zhao J; Zhang W; Ruan X; Hu L; Zeng Y; Hou X; Zheng X; Gao M; Chi J
Small Methods; 2024 Jan; ():e2301310. PubMed ID: 38164884
[TBL] [Abstract][Full Text] [Related]
18. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of a Synthetic Amino Acid into dCas9 Improves Control of Gene Silencing.
Koopal B; Kruis AJ; Claassens NJ; Nobrega FL; van der Oost J
ACS Synth Biol; 2019 Feb; 8(2):216-222. PubMed ID: 30668910
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells.
Xu D; Wang Q; Gruber A; Björkholm M; Chen Z; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P
Oncogene; 2000 Oct; 19(45):5123-33. PubMed ID: 11064449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
